Network-targeting combination therapy of leptomeningeal glioblastoma using multiple synthetic lethal strategies: a

Michael P Castro1,2,3, Bence Sipos4, Saskia Biskup5

  • 1Personalized Cancer Medicine, PLLC, Santa Monica, CA, United States.

Frontiers in Oncology
|November 29, 2023
PubMed

Insights

This study explored a novel network-targeting combination therapy (NTCT) for relapsed leptomeningeal glioblastoma. The approach identified synthetic lethal vulnerabilities, guiding a multi-drug regimen for potential clinical benefit.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Leptomeningeal glioblastoma is an aggressive brain cancer with limited treatment options.
  • Network targeting offers a promising strategy for developing novel combination cancer therapies.
  • Identifying disease-specific vulnerabilities is key to designing effective treatments.